文献速递肿瘤 PET/CT

低剂量[18F]FDG全身PET/CT用于淋巴瘤治疗反应评估

Lymphoma Therapy Response Assessment with Low-Dose [18F]FDG Total-Body PET/CT.
PubMed 文献 · J Nucl Med · 2025-09-02

前瞻性纳入24例淋巴瘤患者,以3.0 MBq/kg为参考标准,在注射后1 h和2 h重建模拟1.0、0.5、0.25、0.125 MBq/kg低剂量图像。SUVpeak、SUVmean、MTV和TLG与参考标准无显著差异;Deauville评分在1 h 0.25 MBq/kg和2 h 1.0 MBq/kg以内与参考标准无显著差异。

要点

  • SUVpeak、SUVmean、MTV和TLG在低剂量与参考标准间无显著差异。
  • Deauville评分在1 h 0.25 MBq/kg和2 h 1.0 MBq/kg以内与参考标准无显著差异。
  • 低于上述剂量限值时Deauville评分显著降低(P < 0.01)。

核心结论

  • 全身PET/CT降低注射活度用于淋巴瘤治疗反应评估可能可行,MTV、TBR或TLG无显著差异。
  • SUVmax和Deauville评分与参考标准可比的下限为注射后1 h 0.25 MBq/kg和2 h 1.0 MBq/kg。

研究设计与样本

  • 前瞻性纳入24例连续淋巴瘤患者,行中期和终末治疗全身PET/CT。
  • 以3.0 MBq/kg [18F]FDG为参考标准,重建模拟1.0、0.5、0.25、0.125 MBq/kg低剂量图像,注射后1 h和2 h采集。

主要发现

  • 共分析191个淋巴瘤病灶。
  • SUVmax在低活度扫描呈统计学显著升高趋势:1 h参考标准6.28 ± 5.87 vs 0.125 MBq/kg 7.76 ± 6.69(P = 0.07);2 h参考标准7.14 ± 7.16 vs 0.125 MBq/kg 8.67 ± 7.62(P = 0.13)。
  • SUVpeak、SUVmean、MTV和TLG在低注射活度与参考标准间无显著差异。
  • 肝脏变异系数随注射活度降低显著增加(P < 0.01);肝脏TBR无显著差异;仅最低注射活度在2 h时血池TBR显著更高(P < 0.01)。
  • 对比噪声比随活度降低显著下降;Deauville评分在1 h 0.25 MBq/kg和2 h 1.0 MBq/kg以内无显著差异,低于此限值时显著降低(P < 0.01)。

关键数值与推荐

  • 参考标准为3.0 MBq/kg [18F]FDG。
  • Deauville评分与参考标准可比的下限:注射后1 h 0.25 MBq/kg,注射后2 h 1.0 MBq/kg。

临床怎么用

  • 作者结论认为全身PET/CT降低注射活度用于淋巴瘤治疗反应评估可能可行。
  • SUVmax和Deauville评分与参考标准可比至1 h 0.25 MBq/kg和2 h 1.0 MBq/kg。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The improved sensitivity of total-body (TB) PET/CT offers the possibility of reducing injected activities. The aim of our study was to define a lower limit of reduced injected activities in [18F]FDG TB PET/CT for interim and end-of-treatment assessment of patients with lymphoma at 2 acquisition times. Methods: Twenty-four consecutive patients with lymphoma who were undergoing interim and end-of-treatment TB PET/CT were prospectively enrolled in this study. An [18F]FDG activity of 3.0 MBq/kg served as the reference standard (RS). Images simulating low doses of 1.0, 0.5, 0.25, and 0.125 MBq/kg were reconstructed at 1 and 2 h after injection. The coefficient of variation of the liver was assessed. Lymphoma lesions were segmented and semiquantitatively compared with the RS using the SUV. Additionally, metabolic tumor volume (MTV) for each lesion, patient-based total MTV, and total-lesion glycolysis (TLG) were analyzed. Semiquantitative parameters were normalized to the liver and blood pool by tumor-to-background ratios (TBRs) and contrast-to-noise ratios. Therapy response was assessed using Deauville criteria. Results: Overall, 191 lymphoma lesions were analyzed. SUVmax demonstrated a trend toward a statistically significant increase in scans with reduced activity at 1 h after injection (6.28 ± 5.87 for RS vs. 7.76 ± 6.69 for 0.125 MBq/kg; P = 0.07) and 2 h after injection (7.14 ± 7.16 for RS vs. 8.67 ± 7.62 for 0.125 MBq/kg; P = 0.13). SUVpeak, SUVmean, MTV, and TLG did not significantly differ between the reduced injected activities and the RS. The coefficient of variation for the liver increased significantly with decreasing injected activities (P < 0.01). The TBR for the liver did not differ significantly, whereas the TBR for the blood pool was significantly higher only for the lowest injected activity (P < 0.01) at 2 h after injection. The contrast-to-noise ratio significantly decreased with reduced activities. Deauville scores did not differ significantly, up to a dose of 0.25 MBq/kg at 1 h after injection and a dose of 1.0 MBq/kg at 2 h after injection. Below this limit, we noted significantly lower Deauville scores for reduced injected activities (P < 0.01). Conclusion: Reduction of injected activities with [18F]FDG TB PET/CT for therapy response assessment in patients with lymphoma may be possible and does not result in significant differences in MTV, TBR, or TLG. SUVmax and Deauville scores were comparable to the RS to a lower limit of 0.25 MBq/kg at 1 h after injection and 1.0 MBq/kg at 2 h after injection.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Mingels C, Chung KJ, Nalbant H, et al. Lymphoma Therapy Response Assessment with Low-Dose [18F]FDG Total-Body PET/CT. J Nucl Med. 2025. PMID: 40813234. doi:10.2967/jnumed.124.268841

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。